1002101-19-0

1002101-19-0 structure

Name: PBI-4050
Chemical Name: (3-pentylphenyl)acetic acid
CAS Number: 1002101-19-0
Molecular Formula: C₁₃H₁₈O₂
Molecular Weight: 206.28100
Catalog: Signaling Pathways GPCR/G Protein GPR40
Create Date: 2018-03-05 17:09:28
Modify Date: 2024-01-23 15:34:58
Setogepram (PBI-4050) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Setogepram (PBI-4050) decreases renal, liver and pancreatic fibrosis[1][2]. Setogepram (PBI-4050) exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].

Name	(3-pentylphenyl)acetic acid
Synonyms	3-pentylphenylacetic acid

Description	Setogepram (PBI-4050) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Setogepram (PBI-4050) decreases renal, liver and pancreatic fibrosis[1][2]. Setogepram (PBI-4050) exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> GPR40 Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> GPR84
Target	GPR40, GPR84[1]
In Vitro	Setogepram (PBI-4050; 500 µM; 24 hours) inhibits TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation[2]. Setogepram (PBI-4050; 250 or 500 µM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis[2]. Cell Proliferation Assay[2] Cell Line: HSCs Concentration: 250 or 500 µM Incubation Time: 24 hours Result: Inhibited TGF-β-activated HSC proliferation. TGF-β (10 ng/mL) increased HSC proliferation by 10%. Cell Cycle Analysis[2] Cell Line: HSCs Concentration: 250 µM, 500 µM Incubation Time: 24 hours Result: Inhibited cell cycle progression.
In Vivo	Setogepram (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS-/-db/db mice[1]. Animal Model: Type 2 diabetes eNOS-/-db/db mice[1] Dosage: 100 mg/kg/day Administration: Given via daily gavage from 8-20 weeks Result: Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.
References	[1]. Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365. [2]. Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81.

Molecular Formula	C₁₃H₁₈O₂
Molecular Weight	206.28100
Exact Mass	206.13100
PSA	37.30000
LogP	3.04640
Storage condition	-20°C

1002101-19-0	1254472-97-3
1627694-81-8	130694-74-5
124172-53-8	1001349-19-4
95343-61-6	110590-81-3
2749749-52-6	1158522-08-7
940364-43-2	2172444-11-8
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4